Home › Therapeutic areas › Neurology › Alzheimer's Disease
Alzheimer's Disease (14 companies)
Companies with an active program in Alzheimer's Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACIU | AC Immune | Neurology Rare | 5 | Phase 3 | $210M | 11 |
| ABOS | Acumen Pharmaceuticals | Neurology | 4 | Phase 2 | $16.6M | 4 |
| AXSM | Axsome Therapeutics | Neurology Rare | 1 | Approved | $7.15B | 15 |
| CGTX | Cognition Therapeutics | Neurology | 1 | Phase 2 | $59.9M | 2 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $367M | 3 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $52.5M | 5 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 3 | Phase 2 | $236M | 12 |
| LGVN | Longeveron | CardiovascularNeurology Rare | 1 | Phase 2 | $7.1M | 3 |
| MPLT | MapLight Therapeutics | Neurology | 1 | Phase 2 | $365M | 3 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 1 | Phase 2 | $2.9M | 3 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 1 | NDA Submitted | $2.33B | 6 |
| PMN | ProMIS Neurosciences | Neurology Rare | 2 | Phase 1 | $28.9M | 9 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $83.2M | 5 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | $94.6M | 9 |
No companies match.